Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947035 · ClinicalTrials.gov registry record · Phase 2
Molecular Testing to Direct Extent of Initial Thyroid Surgery
A Phase 2 study of Thyroid Cancer, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT02947035: Completed Phase 2 study of Thyroid Cancer, sponsored by University of Pittsburgh.
NCT02947035 is a Phase 2 study of Thyroid Cancer that has completed, run by University of Pittsburgh. The registered enrollment target is 100 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02947035, a Phase 2 study of Thyroid Cancer, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.
Primary Outcome
Histology characteristics of tumor will be assessed including type of cancer, extrathyroidal extension, lymph node metastasis, and margin status to assess if completion thyroidectomy is needed per the 2015 ATA guidelines
Conditions Studied
Interventions
- PROCEDURE Thyroid lobectomy
- PROCEDURE Total thyroidectomy with CCND
Study Locations (2)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 2 |
What the finished NCT02947035 record still lists
NCT02947035 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Thyroid lobectomy is the first listed.
NCT02947035 reports a single indexed study location in Pennsylvania, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02947035 about?
NCT02947035 is a clinical study titled "Molecular Testing to Direct Extent of Initial Thyroid Surgery". The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.
What is the current status of trial NCT02947035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2017-02-01. Estimated completion is 2023-06-01.
What conditions does trial NCT02947035 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT02947035?
The interventions under investigation include: Thyroid lobectomy (PROCEDURE), Total thyroidectomy with CCND (PROCEDURE).
Who is sponsoring clinical trial NCT02947035?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02947035 being conducted?
This trial has 2 study locations across Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02947035's enrollment target sits among peer trials
100 17th of 46 higher than 28 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI